HC Wainwright reissued their buy rating on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $100.00 price objective on the stock. KRRO has been the subject of several other research reports. William Blair assumed coverage on shares of Korro Bio in […]

HC Wainwright reiterated their buy rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. I-Mab Stock Down 2.7 % Shares of NASDAQ:IMAB opened at $1.08 on Tuesday. I-Mab has a fifty-two week low […]

HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock. Capricor Therapeutics Price Performance Shares of CAPR stock opened at $5.05 on Tuesday. Capricor Therapeutics has a 12-month low […]

HC Wainwright reissued their buy rating on shares of RCI Hospitality (NASDAQ:RICK – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $98.00 price target on the restaurant operator’s stock. Separately, StockNews.com upgraded RCI Hospitality from a hold rating to a buy rating in a research note on Wednesday, […]

HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON – Free Report) in a report released on Tuesday, Benzinga reports. The brokerage currently has a $75.00 price objective on the stock. Several other research analysts have also recently weighed in on CGON. Roth Mkm initiated coverage on shares of CG Oncology in […]

HC Wainwright reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $94.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q3 2024 earnings at $0.75 EPS. Several other research […]

Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 50.38% from the stock’s previous close. Several […]

HC Wainwright reiterated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $15.00 price target on the stock. Lisata Therapeutics Trading Up 5.3 % Shares of Lisata Therapeutics stock opened at $3.18 on Wednesday. The stock has […]

Benchmark reiterated their buy rating on shares of Patrick Industries (NASDAQ:PATK – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $145.00 target price on the construction company’s stock. Several other equities analysts also recently weighed in on PATK. Truist Financial lifted their target price […]

CrowdStrike (NASDAQ:CRWD – Get Free Report)‘s stock had its “positive” rating reissued by research analysts at Susquehanna in a report issued on Thursday, Benzinga reports. They currently have a $310.00 price objective on the stock. Susquehanna’s price target suggests a potential upside of 3.39% from the company’s previous close. CRWD has been the topic of […]

StockNews.com downgraded shares of RCI Hospitality (NASDAQ:RICK – Free Report) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning. Separately, HC Wainwright reissued a buy rating and set a $98.00 price target on shares of RCI Hospitality in a research report on Tuesday. View Our Latest […]

Korro Bio (NASDAQ:KRRO – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Royal Bank of Canada in a report issued on Thursday, Benzinga reports. They presently have a $95.00 price objective on the stock. Royal Bank of Canada’s target price would suggest a potential upside of 161.49% from the company’s […]